New drug HSK55879 enters first human safety trial
NCT ID NCT07521345
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 study tests the safety and tolerability of a new drug called HSK55879 in 46 healthy adults aged 18 to 45. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather early safety data, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK55879
- What could go wrong
- This is a very early Phase 1 study in healthy people, so it cannot show any treatment benefit. The drug may prove unsafe or ineffective in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALHTY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two experimental drugs be taken together safely? a trial seeks answers
- Morning larks vs night owls: does chronotype shape balance and brain power?
- New portable breath analyzer could bring Lab-Grade fitness testing to the field
- Inside the elite Athlete's body: hormones and brain chemicals measured during All-Out rowing
- Alzheimer's memory boost? study tests action and video tricks
- Your body shape may change how drugs work